PharmGen Science Inc (004720) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of PharmGen Science Inc KRW 2,837, price KRW 2,825, upside +0.4%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch PharmGen Science Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 2,710 KRW – 16,150 KRW · fair‑value band 2,119 KRW – 3,835 KRW · the 2,825 KRW price screens below the 2,837 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow PharmGen Science in your weekly email
Every Wednesday you see whether PharmGen Science is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name.
Show more
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1957 and is headquartered in Hwaseong-si, South Korea.
Stock analysis
PharmGen Science Inc (004720) currently trades at 2,825 KRW, while our model-based Fair Value estimate is 2,837 KRW, implying the stock looks roughly 0.4% fairly valued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 5,634 KRW per share, and 11 of the 13 models we run sit above the 2,825 KRW price.
Bear case: the Earnings-Based group reads lowest at 2,082 KRW, and 2 of the 13 models stay below the price. Evidence for this calculation is low.
Scenario range: 2,119 KRW (bear) to 3,835 KRW (bull), the price of 2,825 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
PharmGen Science Inc reported revenue of 173B KRW in FY2025 versus 110B KRW in FY2021, a compound +12.0%/yr. Reported net income was −117B KRW in FY2025.
Key figures
Market cap 76.1B KRW (≈ $56.0M) · P/S ratio 0.44 · Net margin −67.4% · Return on equity 0.1% · Return on assets (EBIT) 1.8% · Operating margin 4.8% · Revenue (TTM) 172B KRW · Revenue growth (YoY) +0.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 38% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 1% fair-value upside, at 0%, 004720 screens richer than that median.
Fair Value models
Bear 2,119 KRWFair Value 2,837 KRWBull 3,835 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.65/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
Start year 2020 (pandemic). Over 10 years: +11.1% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−0.5% (2020) → 3.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +9.1% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside+0% · Above median
Profitability
Return on equity (TTM)0% · Bottom 25%
Return on assets2% · Bottom 25%
Net margin (TTM)0% · Bottom 25%
Operating margin (TTM)5% · Bottom 25%
Growth and dividend
Revenue growth1% · Below median
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is PharmGen Science Inc (004720) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 2,837 KRW versus a price of 2,825 KRW, about +0% upside (fairly valued).
What is the fair value of 004720?
Our model-based fair value for PharmGen Science Inc is 2,837 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 2,825 KRW.
What is the quality score of 004720?
PharmGen Science Inc has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PharmGen Science Inc (004720)?
Our model-based price target is the fair value of 2,837 KRW (as of Sep 24, 2026) from 13 valuation models. Cautious scenario 2,119 KRW, optimistic scenario 3,835 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the PharmGen Science Inc stock forecast for 2026?
Our models put fair value at 2,837 KRW, about +0% upside versus a price of 2,825 KRW (fairly valued). Cautious scenario 2,119 KRW, optimistic scenario 3,835 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of PharmGen Science Inc (004720)?
PharmGen Science Inc reported trailing-twelve-month revenue of about 172B KRW (latest available figure, as of Sep 24, 2026).
What growth is priced into PharmGen Science Inc (004720)?
For today's price to be fair in a discounted-cash-flow model, PharmGen Science Inc would have to grow free cash flow by +11.3 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.4 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 004720 use?
Our models discount PharmGen Science Inc at 11.6 %: a base by market capitalisation (micro), damped by beta 0.24, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For PharmGen Science Inc that is +11.3 % per year a year over ten years, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has PharmGen Science Inc (004720) delivered so far?
Over the past 5 years revenue at PharmGen Science Inc grew +12.4 % a year. The price currently implies +11.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of PharmGen Science Inc (004720) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into PharmGen Science Inc (+11.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of PharmGen Science Inc (004720)?
The free-cash-flow yield on the price is 4.28 %: that much free cash flow PharmGen Science Inc produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of PharmGen Science Inc (004720)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PharmGen Science Inc it is 2,837 KRW per share (as of Sep 24, 2026), against a price of 2,825 KRW. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is PharmGen Science Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 004720 trades below its calculated fair value: price 2,825 KRW, fair value 2,837 KRW, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 004720?
No. The price is what the market pays today (2,825 KRW); the fair value is what the company's own numbers justify (2,837 KRW). For PharmGen Science Inc the two are 12.21 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is PharmGen Science Inc worth?
The market values PharmGen Science Inc at about 76.1B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 2,825 KRW; our models calculate a fair value of 2,837 KRW per share.
What do the bullish and bearish scenarios say about 004720?
Our models span a range for PharmGen Science Inc: cautious scenario 2,119 KRW, base 2,837 KRW, optimistic 3,835 KRW per share (as of Sep 24, 2026, price 2,825 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PharmGen Science Inc (004720)?
Balance-sheet figures for PharmGen Science Inc (as of Sep 24, 2026): return on equity 0.1%, debt of 0.00 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 004720 from its 52-week high?
PharmGen Science Inc trades at 2,825 KRW, about 38% below its 52-week high of 4,530 KRW and 4% above the low of 2,710 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 2,837 KRW is for.
Which stocks are comparable to PharmGen Science Inc?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PharmGen Science Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 2,825 KRW, calculated fair value 2,837 KRW (+0%), Quality Score 43/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 004720 calculated?
We run PharmGen Science Inc through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2,837 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. PharmGen Science Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PharmGen Science Inc (004720)?
The closing price on Sep 23, 2026 was 2,825 KRW. Our model-based fair value is 2,837 KRW, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PharmGen Science Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (2,119 KRW to 3,835 KRW) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of PharmGen Science Inc
How large is the market capitalisation of PharmGen Science Inc (004720)?
The market capitalisation of PharmGen Science Inc is 76.1B KRW (≈ $56.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PharmGen Science Inc (004720)?
The price-to-sales ratio of PharmGen Science Inc is 0.44 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of PharmGen Science Inc (004720)?
The net margin of PharmGen Science Inc is −67.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PharmGen Science Inc (004720)?
The return on equity (ROE) of PharmGen Science Inc is 0.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PharmGen Science Inc (004720)?
On an EBIT basis the return on assets of PharmGen Science Inc is 1.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PharmGen Science Inc (004720)?
The operating margin of PharmGen Science Inc is 4.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PharmGen Science Inc (004720)?
Revenue at PharmGen Science Inc is growing +0.9% versus a year earlier (3y avg +4.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at PharmGen Science Inc (004720)?
Earnings per share at PharmGen Science Inc are growing +55.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does PharmGen Science Inc (004720) carry?
The net debt of PharmGen Science Inc is 319M KRW (fiscal year 2024, ≈ 0.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch PharmGen Science Inc in the live analysis
One click puts PharmGen Science Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
